G1-cellcycle Arrest biomarker IGFBP-7 and TIMP-2 as predictors for an Extended postoperative ICU (Intensive Care Unit) stay following vascular surgery at the abdominal aorta

G1-cellcycle Arrest biomarker IGFBP-7 and TIMP-2 as predictors for an Extended postoperative ICU (Intensive Care Unit) stay following vascular surgery at the abdominal aorta - ROCCET-Trial

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00013757

Enrollment

100

Registered

2018-01-29

Start date

2018-02-05

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

N17.9

Interventions

Group 1: This trial intends to enable physicans to predict kidney injury due to aortic surgery (via laparotomy or endovascular) at an early stage. This would allow early identificaton of risk patients

Eligibility

Sex/Gender

All

Age

18 Years to 108 Years

Inclusion criteria

Inclusion criteria: aortic surgery (via laparotomy or endovascular)

Exclusion criteria

Exclusion criteria: - not fulfilling the inclusion criteria - not able to give writen informed consent - not willing to participate

Design outcomes

Primary

Measure	Time frame
For the prediction of a moderate or severe acute kidney injury blood and urine samples will be collected immediately before and after the surgical procedure, as well as at the first postoperative day. Standard laboratory and G1-cellcycle Arrest biomarker “insulin like growth factor binding protein-7” (IGFBP-7) and “tissue inhibitor of metalloproteinase-2” (TIMP-2) will be measured. IGFBP-7 and TIMP-2 Levels will be measured by a Point of care device in Urine samples. The standard laboratory markers (e.g. creatinine) will be measured in plasma samples at the central lab (University Hospital Heidelberg).	—

Measure

Time frame

For the prediction of a moderate or severe acute kidney injury blood and urine samples will be collected immediately before and after the surgical procedure, as well as at the first postoperative day. Standard laboratory and G1-cellcycle Arrest biomarker “insulin like growth factor binding protein-7” (IGFBP-7) and “tissue inhibitor of metalloproteinase-2” (TIMP-2) will be measured. IGFBP-7 and TIMP-2 Levels will be measured by a Point of care device in Urine samples. The standard laboratory markers (e.g. creatinine) will be measured in plasma samples at the central lab (University Hospital Heidelberg).

—

Secondary

Measure	Time frame
Association between IGFBP-7xTIMP-2 urine concentrations and the kidney function immediately after the surgical procedure and at the first postoperative day.	—

Countries

Germany

Contacts

Public ContactThorsten Brenner

Klinik für Anästhesiologie

Thorsten.Brenner@med.uni-heidelberg.de06221-56-39418

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026